Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • ID: 3972704
  • Report
  • 144 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Advinus Therapeutics Ltd
  • BeiGene, Ltd.
  • Celgene Corporation
  • Genentech, Inc.
  • Merck KGaA
  • MORE
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016

‘Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
- Certain sections in the report may be removed or altered based on the availability and relevance of data.
- Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Advinus Therapeutics Ltd
  • BeiGene, Ltd.
  • Celgene Corporation
  • Genentech, Inc.
  • Merck KGaA
  • MORE
Introduction

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Overview

Therapeutics Development

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Stage of Development

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Therapy Area

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Indication

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Companies

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Universities/Institutes

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Companies Involved in Therapeutics Development

AbbVie Inc

ACEA Biosciences, Inc.

Advinus Therapeutics Ltd

ArQule, Inc.

BeiGene, Ltd.

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Bristol-Myers Squibb Company

Celgene Corporation

CrystalGenomics, Inc.

Genentech, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

LSK BioPartners, Inc.

Merck KGaA

Ono Pharmaceutical Co., Ltd.

Pharmacyclics, Inc.

Principia Biopharma Inc.

Redx Pharma Plc

Simcere Pharmaceutical Group

Sunesis Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Drug Profiles

ABBV-599 - Drug Profile

AC-058 - Drug Profile

acalabrutinib - Drug Profile

Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia - Drug Profile

ARQ-531 - Drug Profile

BGB-3111 - Drug Profile

BIIB-068 - Drug Profile

BMS-986142 - Drug Profile

BMS-986195 - Drug Profile

CG-026806 - Drug Profile

CG-036806 - Drug Profile

Drug to Inhibit BTK for Undisclosed Indications - Drug Profile

DTRMWXHS-12 - Drug Profile

EBI-1266 - Drug Profile

EBI-1367 - Drug Profile

HCI-1401 - Drug Profile

HCI-1684 - Drug Profile

HM-71224 - Drug Profile

ibrutinib - Drug Profile

M-2951 - Drug Profile

M-7583 - Drug Profile

ONO-4059 - Drug Profile

PLS-123 - Drug Profile

PNQ-154 - Drug Profile

PNQ-849 - Drug Profile

PRN-1008 - Drug Profile

PRN-473 - Drug Profile

RDX-002 - Drug Profile

RG-7845 - Drug Profile

Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis - Drug Profile

Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders and Rheumatoid Arthritis - Drug Profile

Small Molecule to Inhibit BTK for Immunology - Drug Profile

Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer - Drug Profile

Small Molecule to Inhibit BTK for Oncology - Drug Profile

Small Molecule to Target BTK for Immunology - Drug Profile

Small Molecules to Inhibit BTK for Oncology - Drug Profile

Small Molecules to Inhibit BTK for Rheumatoid Arthritis - Drug Profile

SNS-062 - Drug Profile

spebrutinib besylate - Drug Profile

TAK-020 - Drug Profile

X-022 - Drug Profile

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Dormant Projects

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Development by Companies, H2 2016 (Contd..6)

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by AbbVie Inc, H2 2016

Pipeline by ACEA Biosciences, Inc., H2 2016

Pipeline by Advinus Therapeutics Ltd, H2 2016

Pipeline by ArQule, Inc., H2 2016

Pipeline by BeiGene, Ltd., H2 2016

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016

Pipeline by Biogen Inc, H2 2016

Pipeline by Bristol-Myers Squibb Company, H2 2016

Pipeline by Celgene Corporation, H2 2016

Pipeline by CrystalGenomics, Inc., H2 2016

Pipeline by Genentech, Inc., H2 2016

Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016

Pipeline by LSK BioPartners, Inc., H2 2016

Pipeline by Merck KGaA, H2 2016

Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Pipeline by Pharmacyclics, Inc., H2 2016

Pipeline by Principia Biopharma Inc., H2 2016

Pipeline by Redx Pharma Plc, H2 2016

Pipeline by Simcere Pharmaceutical Group, H2 2016

Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Dormant Projects (Contd..2), H2 2016

Discontinued Products, H2 2016

List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • ACEA Biosciences, Inc.
  • Advinus Therapeutics Ltd
  • ArQule, Inc.
  • BeiGene, Ltd.
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Biogen Inc
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • CrystalGenomics, Inc.
  • Genentech, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • LSK BioPartners, Inc.
  • Merck KGaA
  • Ono Pharmaceutical Co., Ltd.
  • Pharmacyclics, Inc.
  • Principia Biopharma Inc.
  • Redx Pharma Plc
  • Simcere Pharmaceutical Group
  • Sunesis Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll